的选择。但由于本研究时间较短(仅16周),纳入样本量偏小,故仍有待于更大样本的长期的临床观察结果进一步证实。

参考文献:

[1] Giugliano D, Standl E, Vilsboll T, *et al*. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? [J]. Acta Diabetol, 2009, 46(3): 173-181.

[2] Nauck M A. Unraveling the science of incretin biology [J]. Eur J Intern Med, 2009, 20(Suppl 2): S303-S308.

[3] Gupta N A, Mells J, Dunham R M, *et al*. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis *in vitro* by modulating elements of the insulin signaling pathway [J]. Hepatology, 2010, 51(5): 1584-1592.

[4] Nathan D M, Buse J B, Davidson M B, *et al*. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [J]. Diabetes Care, 2009, 32(1): 193-203.

[5] Eng J, Kleinman W A, Singh L, *et al*. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas [J]. J Biol Chem, 1992, 267(11): 7402-7405.

[6] Boulton D, Tang A, Patel C, *et al*. Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment [J]. Endocr Abstr, 2009, 20: 357.

[7] Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1) [J]. Cell Signal, 2010, 22(1): 1-8.

[8] Fehse F, Trautmann M, Holst J J, *et al*. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2005, 90(11): 5991-5997.

[9] Buse J B, Rosenstock J, Sesti G, *et al*. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J]. Lancet, 2009, 374(9683): 39-47.

[10] Erdogdu O, Nathanson D, Sjoholm A, *et al*. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J]. Mol Cell Endocrinol, 2010, 325(1/2): 26-35.

[11] 骆天红, 郑以漫. 胰升糖素样肽1对胰岛β细胞作用的研究进展[J]. 中华内分泌代谢杂志, 2008, 24(6):附录6b-1-4.

[12] Bunck M C, Corner A, Eliasson B, *et al*. One-year treatment with exenatide *vs*. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress [J]. Atherosclerosis, 2010, 212(1): 223-229.

[13] Kawakami A, Osaka M, Aikawa M, *et al*. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation [J]. Circ Res, 2008, 103(12): 1402-1409.

[14] Klonoff D C, Buse J B, Nielsen L L, *et al*. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J]. Curr Med Res Opin, 2008, 24(1): 275-286.

[15] Monami M, Lamanna C, Desideri C M, *et al*. DPP-4 inhibitors and lipids: systematic review and meta-analysis [J]. Adv Ther, 2012, 29(1): 14-25.

(**收稿**:2013-02-11;**修回**:2013-04-11)

(编辑 栾 嘉)

本刊常务编委靳风烁教授被评为“科学中国人2012年度人物”

由中国科协、《中国科学人》杂志社主办的“科学中国人2012年度人物”颁奖典礼于2013年6月22日在北京隆重举行,中国人大前副主任顾秀莲、中国科协、航天部、电子工业信息部领导、中国科学院院士、中国工程院院士等1 000余人出席大会。本刊第九届常务编委靳风烁教授获得生物医学领域年度人物。“科学中国人年度人物”举办12年来先后表彰科学院、工程院两院院士150余人,各行业有突出贡献专家近千人。

靳风烁教授在泌尿肿瘤的基础研究与临床诊治中取得了显著的成绩,其关于前列腺癌的研究成果发表在国际著名SCI收录期刊《Cancer research》,受邀加入中国前列腺癌联盟专家组;他研究提出的中西医结合治疗雄激素非依赖前列腺癌取得了良好的临床效果,为解决雄激素非依赖前列腺癌治疗的世界性难题开辟了新的途径。靳教授多年致力于膀胱肿瘤复发机制与防治的研究,不仅在理论上有所发现,丰富完善了肿瘤自身免疫抑制的“免疫黑洞”理论,临床研究更是大幅度降低了膀胱肿瘤的复发率,该研究先后获得省部级、军队科技进步奖励6项,为提高我国膀胱肿瘤诊治水平作出了重要贡献。靳风烁教授长期坚持在临床一线工作,医德高尚,医术高超,四十年如一日,用自己的双手为无数位患者解除病痛,挽救了无数名患者的生命。



(大坪医院野战外科研究所泌尿外科
孙中义,张 静 供稿)